Plain-English translation of NCT05705648 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a randomized placebo-controlled trial testing whether medium chain triglyceride oil can help improve the cognitive symptoms—like memory problems, brain fog, or difficulty concentrating—that some people experience months after COVID-19 infection. Half of the participants will receive the active oil, while the other half will receive a placebo oil that looks and tastes similar. The study will last 5 months and will help researchers understand whether this nutritional approach can make a real difference.
Many people report persistent cognitive problems—sometimes called "long COVID brain fog"—long after their initial infection has cleared, and current treatment options are limited. This trial is exploring whether this medication might help address these troubling symptoms.
You likely qualify if…
You likely don't qualify if…
You will take 15 milliliters of either the active oil or placebo oil three times a day for 5 months. You won't know which type you're receiving—that's what makes it a placebo-controlled study, which helps researchers see if real improvements are due to the treatment itself. The study will track your cognitive symptoms over this period to see if the treatment helps.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Canada
University of Alberta
Enrollment target
~100 participants
Started
October 2023
Primary completion
July 2026
Age range
22 Years – 50 Years
Last updated on clinicaltrials.gov in July 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.